CY2016021I1 - Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου - Google Patents

Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου

Info

Publication number: CY2016021I1
Authority: CY; Cyprus
Prior art keywords: cancer; virus strain; oncolytic therapy; oncolytic; therapy
Prior art date: 2000-01-21

Application number

CY2016021C

Other languages

English (en)

Other versions

CY2016021I2 (el

Original Assignee

Bio Vex Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-21

Filing date

2016-06-15

Publication date

2016-12-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016021(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-01-21 Priority claimed from GB0001475A external-priority patent/GB0001475D0/en

2000-02-08 Priority claimed from GB0002854A external-priority patent/GB0002854D0/en

2001-01-05 Priority claimed from GB0100288A external-priority patent/GB0100288D0/en

2001-01-06 Priority claimed from GB0100430A external-priority patent/GB0100430D0/en

2016-06-15 Application filed by Bio Vex Limited filed Critical Bio Vex Limited

2016-12-14 Publication of CY2016021I2 publication Critical patent/CY2016021I2/el

2016-12-14 Publication of CY2016021I1 publication Critical patent/CY2016021I1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/869—Herpesviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY2016021C 2000-01-21 2016-06-15 Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου CY2016021I1 (el)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB0001475A GB0001475D0 (en)	2000-01-21	2000-01-21	Virus strains
GB0002854A GB0002854D0 (en)	2000-02-08	2000-02-08	Virus strains
GB0100288A GB0100288D0 (en)	2001-01-05	2001-01-05	Virus strains
GB0100430A GB0100430D0 (en)	2001-01-06	2001-01-06	Virus strains
PCT/GB2001/000229 WO2001053506A2 (en)	2000-01-21	2001-01-22	Virus strains for the oncolytic treatment of cancer

Publications (2)

Publication Number	Publication Date
CY2016021I2 CY2016021I2 (el)	2016-12-14
CY2016021I1 true CY2016021I1 (el)	2016-12-14

Family

ID=27447756

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY2016020C CY2016020I2 (el)	2000-01-21	2016-06-15	Στελεχη ιου του ερπη για γονιδιακη θepαπεια
CY2016021C CY2016021I1 (el)	2000-01-21	2016-06-15	Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY2016020C CY2016020I2 (el)	2000-01-21	2016-06-15	Στελεχη ιου του ερπη για γονιδιακη θepαπεια

Country Status (22)

Country	Link
US (12)	US7223593B2 (el)
EP (4)	EP1252322B2 (el)
JP (6)	JP4921669B2 (el)
KR (2)	KR100802403B1 (el)
CN (2)	CN1418255A (el)
AT (2)	ATE282708T1 (el)
AU (2)	AU2695101A (el)
BE (1)	BE2016C033I2 (el)
BR (3)	BRPI0107737B8 (el)
CA (2)	CA2398343A1 (el)
CY (2)	CY2016020I2 (el)
DE (2)	DE60107203T3 (el)
DK (2)	DK1252323T3 (el)
ES (2)	ES2254359T3 (el)
FR (1)	FR16C0026I2 (el)
GB (2)	GB2375113B (el)
HK (2)	HK1047451B (el)
IL (4)	IL150678A0 (el)
LU (2)	LU93101I2 (el)
NL (2)	NL300821I2 (el)
PT (1)	PT1252322E (el)
WO (2)	WO2001053505A2 (el)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPQ425699A0 (en)	1999-11-25	1999-12-23	University Of Newcastle Research Associates Limited, The	A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
CA2398343A1 (en) *	2000-01-21	2001-07-26	Biovex Limited	Virus strains for the oncolytic treatment of cancer
EP1381280B1 (en)	2001-03-27	2011-05-11	Catherex, Inc.	Viral vectors and their use in therapeutic methods
GB0203285D0 (en)	2002-02-12	2002-03-27	Brown Susanne M	An herpes simplex virus complex
JP2004099584A (ja) *	2002-05-02	2004-04-02	Keio Gijuku	Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en)	2002-12-18	2003-01-09	The University Of Newcastle Research Associates Limited	A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
GB0317511D0 (en)	2003-07-25	2003-08-27	Biovex Ltd	Viral vectors
GB0326798D0 (en) *	2003-11-17	2003-12-24	Crusade Lab Ltd	Methods for generating mutant virus
US7897146B2 (en)	2003-11-17	2011-03-01	Crusade Laboratories Limited	Treatment using herpes simplex virus
WO2005049846A2 (en) *	2003-11-17	2005-06-02	Crusade Laboratories Limited	Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
AU2005228788B2 (en) *	2004-03-31	2010-12-02	Tomoki Todo	Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment
CA2561714A1 (en) *	2004-04-08	2005-10-27	Sangamo Biosciences, Inc.	Methods and compositions for treating neuropathic and neurodegenerative conditions
US9273326B2 (en) *	2004-04-30	2016-03-01	The Brigham And Women's Hospital, Inc.	Tetracycline-regulated gene expression in HSV-1 vectors
ES2564823T3 (es) *	2005-05-27	2016-03-29	Ospedale San Raffaele S.R.L.	Vector génico que comprende miARN
US20080008686A1 (en) *	2006-07-10	2008-01-10	The Brigham And Women's Hospital, Inc.	Tetracycline repressor regulated oncolytic viruses
US8450106B2 (en) *	2007-10-17	2013-05-28	The Ohio State University Research Foundation	Oncolytic virus
US8313896B2 (en) *	2008-04-04	2012-11-20	The General Hospital Corporation	Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
CA2689707A1 (en)	2009-11-16	2011-05-16	Jean-Simon Diallo	Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
CN102666843B (zh)	2009-12-21	2014-10-22	布里格海姆妇女医院公司	单纯疱疹病毒疫苗
CN102146418B (zh) *	2010-02-09	2014-01-15	武汉滨会生物科技有限公司	重组ⅱ型单纯疱疹病毒载体及其制备方法、重组病毒、药物组合物及应用
WO2011101912A1 (ja) *	2010-02-19	2011-08-25	国立大学法人東京大学	組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物
EP2550298B1 (en)	2010-03-23	2015-07-15	The Regents of The University of California	Compositions and methods for self-adjuvanting vaccines against microbes and tumors
WO2011119925A2 (en) *	2010-03-25	2011-09-29	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Synthetic herpes simplex viruses for treatment of cancers
EP2670426B1 (en)	2011-01-31	2017-05-10	The General Hospital Corporation	Multimodal trail molecules and uses in cellular therapies
PT2753355T (pt)	2011-09-08	2019-02-01	Univ New York	Vírus herpes simplex oncolítico e suas utilizações terapêuticas
WO2013052915A2 (en)	2011-10-05	2013-04-11	Genelux Corporation	Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en)	2012-03-16	2013-09-19	Genelux Corporation	Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en)	2012-04-20	2013-10-24	Aladar A. Szalay	Imaging methods for oncolytic virus therapy
EP3473708B1 (en)	2012-07-24	2021-01-27	The General Hospital Corporation	Oncolytic virus therapy for resistant tumors
EP2890720B1 (en)	2012-08-30	2019-07-17	The General Hospital Corporation	Compositions and methods for treating cancer
CN114984062A (zh)	2012-08-30	2022-09-02	安姆根有限公司	使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法
WO2014055960A1 (en)	2012-10-05	2014-04-10	Genelux Corporation	Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
EP3022307A4 (en) *	2013-07-17	2017-04-19	University of Pittsburgh - Of the Commonwealth System of Higher Education	Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production
SG11201602876WA (en)	2013-10-24	2016-05-30	Amgen Inc	Injector and method of assembly
US10758683B2 (en)	2013-10-24	2020-09-01	Amgen Inc.	Drug delivery system with temperature-sensitive control
CN114457044A (zh)	2013-10-25	2022-05-10	普西奥克瑟斯医疗有限公司	武装有异源基因的溶瘤腺病毒
US20160303174A1 (en)	2013-12-11	2016-10-20	The General Hospital Corporation	Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
US10238700B2 (en)	2014-01-02	2019-03-26	Genelux Corporation	Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2015119906A1 (en)	2014-02-05	2015-08-13	Amgen Inc.	Drug delivery system with electromagnetic field generator
MA39818A (fr)	2014-03-30	2017-02-08	Benevir Biopharm Inc	Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2015171777A1 (en)	2014-05-07	2015-11-12	Amgen Inc.	Autoinjector with shock reducing elements
CN113990437A (zh)	2014-06-03	2022-01-28	安姆根有限公司	用于远程处理由药物递送装置收集的数据的系统和方法
EP3206739B1 (en)	2014-10-14	2021-12-01	Amgen Inc.	Drug injection device with visual and audio indicators
SG11201702934TA (en)	2014-10-14	2017-05-30	Halozyme Inc	Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US10799630B2 (en)	2014-12-19	2020-10-13	Amgen Inc.	Drug delivery device with proximity sensor
ES2785311T3 (es)	2014-12-19	2020-10-06	Amgen Inc	Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
DK3250550T3 (da)	2015-01-26	2023-07-17	Ottawa Hospital Res Inst	Sammensætninger og fremgangsmåder til virussensibilisering
MX2017010466A (es)	2015-02-17	2018-06-06	Amgen Inc	Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas.
ES2905870T3 (es)	2015-02-27	2022-04-12	Amgen Inc	Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
GB201505860D0 (en)	2015-04-07	2015-05-20	Agalimmune Ltd	Therapeutic compositions and methods of use for treating cancer
EP3283529B1 (en)	2015-04-17	2023-06-07	The General Hospital Corporation	Agents, systems and methods for treating cancer
SMT202000222T1 (it)	2015-04-30	2020-05-08	Psioxus Therapeutics Ltd	Adenovirus oncolitico che codifica per una proteina b7
WO2016205429A1 (en)	2015-06-15	2016-12-22	New York University	Method of treatment using oncolytic viruses
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
CN105219738A (zh) *	2015-09-21	2016-01-06	北京神源德生物科技有限公司	重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
CA3004530A1 (en)	2015-11-07	2017-05-11	Multivir Inc.	Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
EP3386573B1 (en)	2015-12-09	2019-10-02	Amgen Inc.	Auto-injector with signaling cap
US11155622B2 (en)	2015-12-17	2021-10-26	Psioxus Therapeutics Limited	Virus encoding an anti-TCR-complex antibody or fragment
WO2017120178A1 (en)	2016-01-06	2017-07-13	Amgen Inc.	Auto-injector with signaling electronics
MX2018008413A (es)	2016-01-08	2019-02-20	Replimune Ltd	Virus oncolitico modificado.
EP4122478A1 (en)	2016-02-19	2023-01-25	Virogin Biotech Canada Ltd	Compositions and methods of using stat1/3 inhibitors with oncolytic herpes virus
EP4035711A1 (en)	2016-03-15	2022-08-03	Amgen Inc.	Reducing probability of glass breakage in drug delivery devices
ES2939644T3 (es)	2016-03-25	2023-04-25	Periphagen Inc	Vectores de HSV de alta transducción
CA3019202A1 (en)	2016-04-15	2017-10-19	Alpine Immune Sciences, Inc.	Cd80 variant immunomodulatory proteins and uses thereof
JP7058609B2 (ja)	2016-04-15	2022-04-22	アルパインイミューンサイエンシズインコーポレイテッド	Ｉｃｏｓリガンドバリアント免疫調節タンパク質およびその使用
WO2017189754A1 (en) *	2016-04-26	2017-11-02	Salk Institute For Biological Studies	Hsv--1 oncolytic virus therapies that specificallyh kill alt dependent cancers
US20190106709A1 (en)	2016-04-29	2019-04-11	Virogin Biotech Canada Ltd	Hsv vectors with enhanced replication in cancer cells
US11541168B2 (en)	2016-04-29	2023-01-03	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
EP3455142B1 (en)	2016-05-13	2023-08-09	Amgen Inc.	Vial sleeve assembly
US11238150B2 (en)	2016-05-16	2022-02-01	Amgen Inc.	Data encryption in medical devices with limited computational capability
EP3465124A1 (en)	2016-06-03	2019-04-10	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en)	2016-07-01	2018-01-04	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
US11471488B2 (en)	2016-07-28	2022-10-18	Alpine Immune Sciences, Inc.	CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en)	2016-07-28	2023-12-05	Alpine Immune Sciences, Inc.	CD112 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en)	2016-07-28	2018-02-01	Alpine Immune Sciences, Inc.	Cd155 variant immunomodulatory proteins and uses thereof
EP3490583B1 (en)	2016-08-01	2023-11-29	Virogin Biotech Canada Ltd	Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
WO2018034784A1 (en)	2016-08-17	2018-02-22	Amgen Inc.	Drug delivery device with placement detection
ES2983916T3 (es)	2016-08-29	2024-10-28	Akamis Bio Ltd	Adenovirus armado con acoplador de célula T biespecífica
GB201713765D0 (en)	2017-08-28	2017-10-11	Psioxus Therapeutics Ltd	Modified adenovirus
DK3518948T5 (da)	2016-10-03	2024-09-02	Ottawa Hospital Res Inst	Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira
WO2018075447A1 (en)	2016-10-19	2018-04-26	The Trustees Of Columbia University In The City Of New York	Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
EP3872180A1 (en)	2016-10-20	2021-09-01	Alpine Immune Sciences, Inc.	Secretable variant immunomodulatory proteins and engineered cell therapy
US20200261643A1 (en)	2016-10-25	2020-08-20	Amgen Inc.	On-body injector
KR20190112263A (ko)	2016-12-12	2019-10-04	멀티비르 인코포레이티드	암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
AU2017379835A1 (en)	2016-12-21	2019-07-11	Dnatrix	Armed replication-competent oncolytic adenoviruses
US11298420B2 (en)	2016-12-21	2022-04-12	Memgen, Llc	Armed oncolytic viruses
GB201700350D0 (en)	2017-01-09	2017-02-22	Replimune Ltd	Altered virus
MX2019008432A (es)	2017-01-17	2019-11-18	Amgen Inc	Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
US11920156B2 (en)	2017-02-09	2024-03-05	Indapta Therapeutics, Inc.	Engineered natural killer (NK) cells and compositions and methods thereof
US11369736B2 (en)	2017-02-17	2022-06-28	Amgen Inc.	Cannula insertion and retraction mechanisms
CA3048520A1 (en)	2017-02-17	2018-08-23	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
MX2019010544A (es)	2017-03-06	2019-10-21	Amgen Inc	Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
EP3592402A1 (en)	2017-03-07	2020-01-15	Amgen Inc.	Needle insertion by overpressure
SG11201908062QA (en)	2017-03-09	2019-09-27	Amgen Inc	Insertion mechanism for drug delivery device
CA3056392A1 (en)	2017-03-15	2018-09-20	Amgen Inc.	Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CA3053812A1 (en)	2017-03-16	2018-09-20	Alpine Immune Sciences, Inc.	Pd-l2 variant immunomodulatory proteins and uses thereof
MX2019010887A (es)	2017-03-16	2019-10-15	Alpine Immune Sciences Inc	Proteinas inmunomoduladoras de cb80 variante y usos de estas.
KR20240123406A (ko)	2017-03-16	2024-08-13	알파인 이뮨 사이언시즈, 인코포레이티드	Pd-l1 리간드 변이체 면역조절 단백질 및 그의 용도
MX2019011416A (es)	2017-03-28	2019-11-01	Amgen Inc	Sistema y metodo para conjunto de jeringa y vastago de embolo.
EP3615934A1 (en)	2017-04-28	2020-03-04	Merck Sharp & Dohme Corp.	Biomarkers for cancer therapeutics
CN106974942A (zh) *	2017-05-03	2017-07-25	武汉滨会生物科技股份有限公司	重组溶瘤ii型单纯疱疹病毒在制备抗淋巴瘤、食道癌、乳腺癌、胰腺癌药物中的应用
CA3066399A1 (en)	2017-06-08	2018-12-13	Amgen Inc.	Torque driven drug delivery device
WO2018226515A1 (en)	2017-06-08	2018-12-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
CN107354136A (zh) *	2017-06-15	2017-11-17	杭州睿可特生物科技有限公司	重组单纯疱疹病毒及其制备方法和应用
MA49447A (fr)	2017-06-22	2020-04-29	Amgen Inc	Réduction des impacts/chocs d'activation d'un dispositif
CA3063921A1 (en)	2017-06-23	2018-12-27	Amgen Inc.	Electronic drug delivery device comprising a cap activated by a switch assembly
ES2972207T3 (es)	2017-07-14	2024-06-11	Amgen Inc	Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
IL271173B2 (en)	2017-07-21	2024-04-01	Amgen Inc	Gas permeable sealing element for drug container and methods of assembly
JP7242562B2 (ja)	2017-07-25	2023-03-20	アムジエン・インコーポレーテツド	容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
JP2020528296A (ja)	2017-07-25	2020-09-24	アムジエン・インコーポレーテツド	ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
UY37829A (es)	2017-08-03	2019-01-31	Amgen Inc	Muteínas de interleucina 21 y métodos de tratamiento
JP2020530003A (ja)	2017-08-07	2020-10-15	アムジェンインコーポレイテッド	抗ｐｄ−ｌ１抗体及び腫瘍溶解性ウイルスでの、肝転移を伴う三種陰性乳がん又は結腸直腸がんの処置
US20200164155A1 (en)	2017-08-09	2020-05-28	Amgen Inc.	Hydraulic-pneumatic pressurized chamber drug delivery system
US11077246B2 (en)	2017-08-18	2021-08-03	Amgen Inc.	Wearable injector with sterile adhesive patch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
AU2018329920B2 (en)	2017-09-08	2022-12-01	Amgen Inc.	Inhibitors of KRAS G12C and methods of using the same
EP3681998A1 (en)	2017-09-11	2020-07-22	IMBA-Institut für Molekulare Biotechnologie GmbH	Tumor organoid model
US11759565B2 (en)	2017-10-04	2023-09-19	Amgen Inc.	Flow adapter for drug delivery device
EP3691716B1 (en)	2017-10-06	2023-11-29	Amgen Inc.	Drug delivery device with interlock assembly and related method of assembly
MA50348A (fr)	2017-10-09	2020-08-19	Amgen Inc	Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
US11753458B2 (en)	2017-10-10	2023-09-12	Alpine Immune Sciences, Inc.	CTLA-4 variant immunomodulatory proteins and uses thereof
MA50404A (fr)	2017-10-18	2020-08-26	Alpine Immune Sciences Inc	Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
WO2019084418A1 (en)	2017-10-27	2019-05-02	Merck Sharp & Dohme Corp.	COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER
WO2019090086A1 (en)	2017-11-03	2019-05-09	Amgen Inc.	Systems and approaches for sterilizing a drug delivery device
MA50553A (fr)	2017-11-06	2020-09-16	Amgen Inc	Dispositif d'administration de médicament avec détection de positionnement et de débit
US12053618B2 (en)	2017-11-06	2024-08-06	Amgen Inc.	Fill-finish assemblies and related methods
WO2019094138A1 (en)	2017-11-10	2019-05-16	Amgen Inc.	Plungers for drug delivery devices
CN111278487B (zh)	2017-11-16	2022-06-24	安进公司	用于药物递送装置的门闩锁机构
SG11202003842UA (en)	2017-11-24	2020-06-29	Ottawa Hospital Res Inst	Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
BR112020013236A2 (pt)	2018-01-03	2020-12-01	Alpine Immune Sciences, Inc.	proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
EP3737694B1 (en)	2018-01-12	2023-03-01	Amgen Inc.	Anti-pd-1 antibodies and methods of treatment
US11390650B2 (en)	2018-02-05	2022-07-19	The Brigham And Women's Hospital, Inc.	Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
WO2020036635A2 (en)	2018-03-19	2020-02-20	Multivir Inc.	Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
EP3774877A1 (en) *	2018-03-28	2021-02-17	Bioxodes	Anticoagulant fusion proteins and uses thereof
US20210236625A1 (en)	2018-05-01	2021-08-05	Albert Einstein College Of Medicine	HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
AU2019282239B2 (en)	2018-06-04	2024-06-06	Calidi Biotherapeutics (Nevada), Inc.	Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en)	2018-06-04	2022-11-22	Calidi Biotherapeutics, Inc.	Cell-based vehicles for potentiation of viral therapy
AU2019282755A1 (en) *	2018-06-08	2021-01-28	The Board Of Trustees Of University Of Illinois	Recombinant Herpes Simplex Virus for cancer immunotherapy
EP3807304A1 (en) *	2018-06-15	2021-04-21	Children's Hospital Medical Center	Polypeptides, nucleic acid molecules, compositions, and related methods
US12065476B2 (en)	2018-06-15	2024-08-20	Alpine Immune Sciences, Inc.	PD-1 variant immunomodulatory proteins and uses thereof
US20210260279A1 (en)	2018-07-24	2021-08-26	Amgen Inc.	Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
WO2020023444A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Delivery devices for administering drugs
US20210128844A1 (en)	2018-07-24	2021-05-06	Amgen Inc.	Delivery devices for administering drugs
MA53320A (fr)	2018-07-31	2021-11-03	Amgen Inc	Ensemble de trajet de fluide pour dispositif d'administration de médicament
CN109161561A (zh) *	2018-08-09	2019-01-08	湖北科技学院	一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
WO2020047161A2 (en)	2018-08-28	2020-03-05	Actym Therapeutics, Inc.	Engineered immunostimulatory bacterial strains and uses thereof
WO2020068623A1 (en)	2018-09-24	2020-04-02	Amgen Inc.	Interventional dosing systems and methods
IL281469B2 (en)	2018-09-28	2024-08-01	Amgen Inc	Muscle wire escapement activation assembly for a drug delivery device
IL281712B2 (en)	2018-10-02	2025-03-01	Amgen Inc	Injection systems for drug delivery with internal power transmission
AU2019355979B2 (en)	2018-10-05	2024-12-05	Amgen Inc.	Drug delivery device having dose indicator
AR116703A1 (es)	2018-10-15	2021-06-02	Amgen Inc	Proceso de ensamblaje de plataforma para un dispositivo de administración de fármacos
IL281894B2 (en)	2018-10-15	2024-12-01	Amgen Inc	Drug delivery device having damping mechanism
WO2020091981A1 (en)	2018-11-01	2020-05-07	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
EP3873566B1 (en)	2018-11-01	2024-11-27	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
JP7329593B2 (ja)	2018-11-06	2023-08-18	カリディ・バイオセラピューティクス・インコーポレイテッド	細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
CN113891934A (zh)	2018-11-21	2022-01-04	因达普塔治疗公司	扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
TW202038947A (zh)	2018-11-28	2020-11-01	德商創新分子有限責任公司	在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
EP3887394A2 (en)	2018-11-30	2021-10-06	Alpine Immune Sciences, Inc.	Cd86 variant immunomodulatory proteins and uses thereof
JP7566750B2 (ja)	2018-12-27	2024-10-15	アムジェンインコーポレイテッド	凍結乾燥ウイルス製剤
MX2021008832A (es) *	2019-02-08	2021-09-08	Krystal Biotech Inc	Composiciones y metodos para la administracion de polipeptidos cftr.
CN113748124A (zh)	2019-02-27	2021-12-03	阿克蒂姆治疗有限公司	工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌
US12024709B2 (en)	2019-02-27	2024-07-02	Actym Therapeutics, Inc.	Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20220090133A1 (en)	2019-03-05	2022-03-24	Amgen Inc.	Use of oncolytic viruses for the treatment of cancer
WO2020185298A1 (en) *	2019-03-14	2020-09-17	Massachusetts Institute Of Technology	Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof
TW202102543A (zh)	2019-03-29	2021-01-16	美商安進公司	溶瘤病毒在癌症新輔助療法中之用途
JP7510952B2 (ja)	2019-04-24	2024-07-04	アムジエン・インコーポレーテツド	シリンジ滅菌確認アセンブリ及び方法
AU2020337250A1 (en)	2019-08-23	2022-03-03	Amgen Inc.	Drug delivery device with configurable needle shield engagement components and related methods
WO2021113644A1 (en)	2019-12-05	2021-06-10	Multivir Inc.	Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021127524A1 (en) *	2019-12-20	2021-06-24	Krystal Biotech, Inc.	Compositions and methods for gene delivery to the airways and/or lungs
US20230190801A1 (en)	2020-04-22	2023-06-22	Indapta Therapeutics, Inc.	Natural killer (nk) cell compositions and methods for generating same
WO2022015407A1 (en) *	2020-07-16	2022-01-20	Massachusetts Institute Of Technology	Simultaneous delivery of cancer treatment programs to tumor and immune cells
WO2022147480A1 (en)	2020-12-30	2022-07-07	Ansun Biopharma, Inc.	Oncolytic virus encoding sialidase and multispecific immune cell engager
CA3207359A1 (en)	2021-02-05	2022-08-11	Cecile Chartier-Courtaud	Adjuvant therapy for cancer
EP4341161A1 (en)	2021-05-21	2024-03-27	Amgen Inc.	Method of optimizing a filling recipe for a drug container
CN115707781A (zh) *	2021-08-20	2023-02-21	广东东阳光药业有限公司	Hsv病毒载体及其应用
WO2024251286A1 (zh) *	2023-06-08	2024-12-12	上海药明生物医药有限公司	溶瘤性hsv-1临床分离株、定向进化株、感染性克隆及应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5163949A (en) *	1990-03-02	1992-11-17	Bonutti Peter M	Fluid operated retractors
US6610287B1 (en)	1990-04-16	2003-08-26	The General Hospital Corporation	Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) *	1990-09-10	1994-07-12	Arch Development Corporation	Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en)	1991-01-31	1991-03-13	Smithkline Beecham Biolog	Novel vaccine
GB9202933D0 (en)	1992-02-12	1992-03-25	Smithkline Beecham Biolog	Vaccines
CA2132976C (en)	1992-03-31	2003-12-30	Bernard Roizman	Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
GB9325496D0 (en)	1993-12-14	1994-02-16	Smithkline Beecham Biolog	Vaccines
US5728379A (en)	1994-06-23	1998-03-17	Georgetown University	Tumor- or cell-specific herpes simplex virus replication
US5585096A (en)	1994-06-23	1996-12-17	Georgetown University	Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9423663D0 (en) *	1994-11-23	1995-01-11	Cantab Pharma Res	Viral preparations, immunogens, and vaccines
NL9500216A (nl) *	1995-02-06	1996-09-02	Bio Pharma Sciences Bv	Farmaceutische samenstelling voor de behandeling van herpes.
JPH11500014A (ja) *	1995-02-21	1999-01-06	キャンタブファーマシューティカルズリサーチリミティド	ウイルス調製物、ベクター、免疫原、及びワクチン
ZA966287B (en)	1995-07-27	1998-03-09	American Cyanamid Co	Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
US6344445B1 (en) *	1995-10-19	2002-02-05	Cantab Pharmaceutical Research Limited	Herpes virus vectors and their uses
GB9524973D0 (en)	1995-12-06	1996-02-07	Lynxvale Ltd	Viral vectors
EP0895476B1 (en)	1996-01-25	2003-06-04	The University Court Of The University Of Glasgow	Hsv mutant 1716 for the treatment of mesotheliomas
US5824318A (en)	1996-07-24	1998-10-20	American Cyanamid Company	Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US5876923A (en) *	1996-07-26	1999-03-02	Arch Development Corporation	Herpes simplex virus ICP4 as an inhibitor of apoptosis
GB9615794D0 (en) *	1996-07-26	1996-09-04	Medical Res Council	Mutant herpes simplex virus strains and uses thereof
GB2322130B (en)	1997-02-13	2000-12-20	Secr Defence	A vaccine against Simian Herpes B virus
GB9704046D0 (en) *	1997-02-27	1997-04-16	Univ Leeds	Arrestable therapeutic
US6051428A (en) *	1997-03-21	2000-04-18	Sloan-Kettering Institute For Cancer Research	Rapid production of autologous tumor vaccines
US5998174A (en) *	1997-05-12	1999-12-07	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Multigene vectors
US6379674B1 (en)	1997-08-12	2002-04-30	Georgetown University	Use of herpes vectors for tumor therapy
US20030044384A1 (en) *	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
GB9801930D0 (en)	1998-01-29	1998-03-25	Univ London	Mutant herpes simplex viruses and uses thereof
CA2323067A1 (en)	1998-03-12	1999-09-16	The Trustees Of The University Of Pennsylvania	Producer cells for replication selective viruses in the treatment of malignancy
GB9810904D0 (en)	1998-05-20	1998-07-22	Univ London	Mutant herpes simplex viruses and uses thereof
GB9816781D0 (en)	1998-07-31	1998-09-30	Univ London	Herpes virus vectors for dendritic cells
US6713067B2 (en) *	1998-07-31	2004-03-30	Biovex Limited	Herpes viruses for immune modulation
AU5467899A (en)	1998-08-07	2000-02-28	University Of Washington	Immunological herpes simplex virus antigens and methods for use thereof
EP1141338A4 (en) *	1998-12-31	2002-09-25	Arch Dev Corp	RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES
US6428968B1 (en) *	1999-03-15	2002-08-06	The Trustees Of The University Of Pennsylvania	Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
ATE371031T1 (de)	1999-06-08	2007-09-15	Uab Research Foundation	Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
US6764675B1 (en) *	1999-06-08	2004-07-20	The Uab Research Foundation	Herpes simplex virus expressing foreign genes and method for treating cancers therewith
IL131212A0 (en) *	1999-08-03	2001-01-28	Yissum Res Dev Co	Recombinant virus and live-virus vaccines
GB9930419D0 (en)	1999-12-22	2000-02-16	Neurovex Ltd	Replication incompetent herpes virus vectors
GB9930418D0 (en)	1999-12-22	2000-02-16	Neurovex Ltd	Replication incompetent herpes virus vectors
GB0001476D0 (en)	2000-01-21	2000-03-15	Neurovex Ltd	Herpes virus strains
CA2398343A1 (en) *	2000-01-21	2001-07-26	Biovex Limited	Virus strains for the oncolytic treatment of cancer
US7063851B2 (en)	2000-04-12	2006-06-20	Biovex Limited	Herpes viruses for immune modulation
GB0317511D0 (en)	2003-07-25	2003-08-27	Biovex Ltd	Viral vectors
MX2018008413A (es) *	2016-01-08	2019-02-20	Replimune Ltd	Virus oncolitico modificado.

2001
- 2001-01-22 CA CA002398343A patent/CA2398343A1/en not_active Abandoned
- 2001-01-22 ES ES01901292T patent/ES2254359T3/es not_active Expired - Lifetime
- 2001-01-22 CA CA2398335A patent/CA2398335C/en not_active Expired - Lifetime
- 2001-01-22 AT AT01901288T patent/ATE282708T1/de active
- 2001-01-22 BR BRPI0107737A patent/BRPI0107737B8/pt not_active IP Right Cessation
- 2001-01-22 JP JP2001553368A patent/JP4921669B2/ja not_active Expired - Lifetime
- 2001-01-22 JP JP2001553367A patent/JP4810042B2/ja not_active Expired - Lifetime
- 2001-01-22 GB GB0219030A patent/GB2375113B/en not_active Expired - Lifetime
- 2001-01-22 CN CN01806743A patent/CN1418255A/zh active Pending
- 2001-01-22 EP EP01901288A patent/EP1252322B2/en not_active Expired - Lifetime
- 2001-01-22 AU AU2695101A patent/AU2695101A/xx active Pending
- 2001-01-22 WO PCT/GB2001/000225 patent/WO2001053505A2/en active IP Right Grant
- 2001-01-22 DE DE60107203T patent/DE60107203T3/de not_active Expired - Lifetime
- 2001-01-22 GB GB0219033A patent/GB2374873C/en not_active Expired - Lifetime
- 2001-01-22 PT PT01901288T patent/PT1252322E/pt unknown
- 2001-01-22 DK DK01901292T patent/DK1252323T3/da active
- 2001-01-22 US US10/181,697 patent/US7223593B2/en active Active
- 2001-01-22 EP EP05011798A patent/EP1568779A1/en not_active Ceased
- 2001-01-22 AT AT01901292T patent/ATE312189T1/de active
- 2001-01-22 DK DK01901288T patent/DK1252322T4/da active
- 2001-01-22 BR BR0107736-8A patent/BR0107736A/pt not_active IP Right Cessation
- 2001-01-22 BR BRPI0107736A patent/BRPI0107736B8/pt unknown
- 2001-01-22 KR KR1020027009410A patent/KR100802403B1/ko active IP Right Grant
- 2001-01-22 CN CNB018067506A patent/CN1250732C/zh not_active Expired - Lifetime
- 2001-01-22 AU AU2001226951A patent/AU2001226951B8/en active Active
- 2001-01-22 WO PCT/GB2001/000229 patent/WO2001053506A2/en active IP Right Grant
- 2001-01-22 EP EP09014990A patent/EP2177619A1/en not_active Withdrawn
- 2001-01-22 KR KR1020027009412A patent/KR100768408B1/ko active IP Right Review Request
- 2001-01-22 DE DE60115600T patent/DE60115600T2/de not_active Expired - Lifetime
- 2001-01-22 IL IL15067801A patent/IL150678A0/xx unknown
- 2001-01-22 US US10/181,692 patent/US7063835B2/en not_active Expired - Lifetime
- 2001-01-22 ES ES01901288T patent/ES2233600T5/es not_active Expired - Lifetime
- 2001-01-22 IL IL15067701A patent/IL150677A0/xx unknown
- 2001-01-22 EP EP01901292A patent/EP1252323B1/en not_active Expired - Lifetime
2002
- 2002-07-10 IL IL150678A patent/IL150678A/en not_active IP Right Cessation
- 2002-07-10 IL IL150677A patent/IL150677A/en active Protection Beyond IP Right Term
- 2002-11-28 HK HK02108579.0A patent/HK1047451B/zh unknown
- 2002-11-30 HK HK02108740.4A patent/HK1047297B/zh unknown
2006
- 2006-03-10 US US11/372,613 patent/US7537924B2/en not_active Expired - Lifetime
2007
- 2007-04-23 US US11/738,807 patent/US8277818B2/en not_active Expired - Fee Related
2009
- 2009-04-17 US US12/425,952 patent/US20090220460A1/en not_active Abandoned
2011
- 2011-10-31 JP JP2011238257A patent/JP2012072156A/ja active Pending
2012
- 2012-02-17 US US13/399,868 patent/US20120164108A1/en not_active Abandoned
- 2012-08-31 US US13/600,711 patent/US8680068B2/en not_active Expired - Fee Related
2014
- 2014-02-06 US US14/174,521 patent/US20140154215A1/en not_active Abandoned
- 2014-02-07 US US14/175,855 patent/US10301600B2/en not_active Expired - Fee Related
2015
- 2015-04-29 US US14/700,036 patent/US20150232812A1/en not_active Abandoned
- 2015-07-10 JP JP2015138227A patent/JP6424145B2/ja not_active Expired - Lifetime
2016
- 2016-06-08 LU LU93101C patent/LU93101I2/fr unknown
- 2016-06-08 LU LU93100C patent/LU93100I2/fr unknown
- 2016-06-14 NL NL300821C patent/NL300821I2/nl unknown
- 2016-06-14 NL NL300820C patent/NL300820I2/nl unknown
- 2016-06-14 BE BE2016C033C patent/BE2016C033I2/fr unknown
- 2016-06-15 FR FR16C0026C patent/FR16C0026I2/fr active Active
- 2016-06-15 CY CY2016020C patent/CY2016020I2/el unknown
- 2016-06-15 CY CY2016021C patent/CY2016021I1/el unknown
2017
- 2017-03-01 JP JP2017037827A patent/JP2017132779A/ja active Pending
2018
- 2018-11-22 JP JP2018218735A patent/JP6644378B2/ja not_active Expired - Lifetime
2019
- 2019-04-02 US US16/372,800 patent/US20200032218A1/en not_active Abandoned
- 2019-04-05 US US16/376,089 patent/US20200032219A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1250732C (zh)	2006-04-12
US20150232812A1 (en)	2015-08-20
US20070264282A1 (en)	2007-11-15
EP1252322B1 (en)	2004-11-17
US20030091537A1 (en)	2003-05-15
WO2001053505A2 (en)	2001-07-26
IL150678A (en)	2008-12-29
DE60115600D1 (de)	2006-01-12
IL150678A0 (en)	2003-02-12
HK1047451B (zh)	2005-03-18
IL150677A (en)	2008-12-29
CY2016020I1 (el)	2016-12-14
US20120321599A1 (en)	2012-12-20
BRPI0107737B8 (pt)	2021-05-25
JP2003520044A (ja)	2003-07-02
LU93101I2 (fr)	2016-08-08
US20200032219A1 (en)	2020-01-30
EP1252323B1 (en)	2005-12-07
PT1252322E (pt)	2005-03-31
GB2374873B (en)	2004-05-26
AU2694701A (en)	2001-07-31
US7063835B2 (en)	2006-06-20
JP2019048864A (ja)	2019-03-28
KR100768408B1 (ko)	2007-10-18
WO2001053506A3 (en)	2002-05-23
WO2001053506A2 (en)	2001-07-26
US20140154215A1 (en)	2014-06-05
GB0219030D0 (en)	2002-09-25
BRPI0107736B8 (pt)	2021-05-25
AU2695101A (en)	2001-07-31
BR0107736A (pt)	2002-11-19
CY2016021I2 (el)	2016-12-14
NL300821I2 (el)	2016-10-27
AU2001226951B2 (en)	2006-10-05
FR16C0026I1 (el)	2016-07-22
GB2375113A (en)	2002-11-06
JP2003520789A (ja)	2003-07-08
EP1252323A2 (en)	2002-10-30
JP6424145B2 (ja)	2018-11-14
LU93100I2 (fr)	2016-08-08
ATE312189T1 (de)	2005-12-15
US8680068B2 (en)	2014-03-25
AU782659B2 (en)	2005-08-18
BRPI0107737B1 (pt)	2016-11-16
US7537924B2 (en)	2009-05-26
BR0107737A (pt)	2002-11-19
DE60107203T2 (de)	2005-12-01
HK1047297B (zh)	2004-10-21
JP4921669B2 (ja)	2012-04-25
ES2233600T3 (es)	2005-06-16
US20140154216A1 (en)	2014-06-05
US20030113348A1 (en)	2003-06-19
JP6644378B2 (ja)	2020-02-12
DK1252322T3 (da)	2005-03-14
US8277818B2 (en)	2012-10-02
US7223593B2 (en)	2007-05-29
US20090220460A1 (en)	2009-09-03
CA2398335A1 (en)	2001-07-26
ES2233600T5 (es)	2009-06-22
FR16C0026I2 (fr)	2018-04-27
EP1252322A2 (en)	2002-10-30
CA2398343A1 (en)	2001-07-26
JP2012072156A (ja)	2012-04-12
BRPI0107736B1 (pt)	2019-12-17
CN1425073A (zh)	2003-06-18
EP1252322B2 (en)	2009-03-04
JP2017132779A (ja)	2017-08-03
DE60107203D1 (de)	2004-12-23
JP2015221813A (ja)	2015-12-10
DE60107203T3 (de)	2009-07-23
DK1252323T3 (da)	2006-04-03
CN1418255A (zh)	2003-05-14
IL150677A0 (en)	2003-02-12
KR20020080383A (ko)	2002-10-23
EP2177619A1 (en)	2010-04-21
HK1047451A1 (en)	2003-02-21
AU2001226951B8 (en)	2006-10-26
KR20030032913A (ko)	2003-04-26
CY2016020I2 (el)	2016-12-14
CA2398335C (en)	2010-12-07
NL300820I2 (el)	2016-11-17
ES2254359T3 (es)	2006-06-16
DK1252322T4 (da)	2009-06-08
WO2001053505A3 (en)	2001-12-27
BE2016C033I2 (el)	2020-05-20
KR100802403B1 (ko)	2008-02-13
US20120164108A1 (en)	2012-06-28
US20070003571A1 (en)	2007-01-04
US20200032218A1 (en)	2020-01-30
GB2374873C (en)	2011-07-27
GB2375113B (en)	2004-10-20
GB0219033D0 (en)	2002-09-25
EP1568779A1 (en)	2005-08-31
GB2374873A (en)	2002-10-30
DE60115600T2 (de)	2006-07-20
ATE282708T1 (de)	2004-12-15
HK1047297A1 (en)	2003-02-14
JP4810042B2 (ja)	2011-11-09
US10301600B2 (en)	2019-05-28

Publication	Publication Date	Title
CY2016021I1 (el)	2016-12-14	Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου
HUP0400882A3 (en)	2011-01-28	Oncolytic virus therapy
NO20014322D0 (no)	2001-09-05	Vaksine
ATE312624T1 (de)	2005-12-15	Impfstoff gegen hpv
DK1637127T3 (da)	2014-08-04	Terapeutisk mikroskum
NO20031483L (no)	2003-05-28	Vaksine
IS2567B (is)	2009-12-15	Samsetningar gegn veirum
KR100695846B9 (ko)	2021-09-30	암 치료
NO20024172L (no)	2002-11-01	Vaksine
EP1383801A4 (en)	2005-06-01	ANTIBODY AGAINST CANCER
DK1427444T3 (da)	2013-11-04	West-nil-vaccine
DE60002650D1 (de)	2003-06-18	Öladjuvierter Impfstoff
NO20020763D0 (no)	2002-02-15	Vaksine
NO20022245D0 (no)	2002-05-10	Onkolyttiske kombinasjoner for behandling av cancer
NO20033882L (no)	2003-10-31	Vaksine
DK1176964T3 (da)	2007-01-15	Brug af ET743 til behandling af cancer
NO20030239L (no)	2003-03-18	Modifisert virus
PT1220858E (pt)	2004-03-31	Oxazinoquinolonas uteis para o tratamento de infeccoes virais
NO20024255L (no)	2002-09-06	HIV-immun adjuvansterapi
ZA200205470B (en)	2003-10-29	Virus strains for the oncolytic treatment of cancer.
DE10290185D2 (de)	2004-04-15	Tumorvakzine
DE60023981D1 (de)	2005-12-22	Vorverstärkerschaltung
EP1511864A4 (en)	2006-02-15	VIRAL CAPSIDE ASSEMBLY INTERMEDIATES
NO994872D0 (no)	1999-10-06	Reisesafe
IS6184A (is)	2001-11-29	Bóluefni gegn ISA veiru